Pharmaceuticals – Pipeline Overview[1] (as of November 08, 2024)

Phase I

- **HER2/mEGFR Inhibitor** *(BAY 2927088)*
- **DGKzeta Inhibitor** *(BAY 2965501)*
- **CCR8 Ab** *(BAY 3375968)*
- **VVD KEAP1 Act** *(VVD-130037 aka NRF2 Inh, BAY 3605349)*
- **DGKalpha Inh** *(BAY 2862789)*
- **225Ac-Pelgifatamab** *(BAY 3546828)*
- **VVD STAT3 Inhibitor** *(VVD-130850, BAY 3630914)*
- **225Ac-PSMA-Trillium** *(BAY 3563254)*
- **SOS1 Inhibitor** *(BAY 3498264)*
- **SEMA 3a** *(BAY 3401016)*
- **Anti-coagulant** *(BAY 3389934)*
- **Bemdaneprocel** (Parkinson's Disease Cell Therapy) *(BRT-DA01)*
- **Multiple System Atrophy rAAV Gene Therapy** *(AB-1005 aka AAV2-GDNF-MSA)*
- **Pompe Disease rAAV Gene Therapy** *(ACTUS-101)*
- **LGMD2I/R9 rAAV Gene Therapy** *(AB-1003 aka LION-101)*
- **GPR84 Antagonist** *(BAY 3178275)*
- **BAY 2701250**

Phase II

- **Congestive Heart Failure rAAV Gene Therapy** *(AB-1002)*
  // Congestive Heart Failure (GenePHIT)
- **Anti-a2AP** *(BAY 3018250)*
  // Acute Ischemic Stroke; Pulmonary Embolism (SIRIUS)
- **sGC Activator Oral** *(BAY 3283142)*
  // Chronic Kidney Disease (ALPINE-1)
- **Parkinson's Disease rAAV Gene Therapy** *(AB-1005)*
  // Parkinson´s Disease (REGENERATE-PD)

Phase III

- **Darolutamide** (AR Inhibitor)
  // Adjuvant Prostate Cancer (DASL-HiCaP)
  // Prostate Cancer with Biochemical Recurrence after Curative Radiotherapy (ARASTEP)
- **HER2/mEGFR Inhibitor**
  // Advanced Non-small Cell Lung Cancer with HER2 Activating Mutations, 1L (SOHO-02)
- **Finerenone** (MR Antagonist)
  // Heart Failure (HFmr/pEF) (FINEARTS-HF)
  // Non-diabetic Chronic Kidney Disease (FIND-CKD)
  // Chronic Kidney Disease in Type 1 Diabetes (FINE-ONE)
- **Vericiguat** (sGC Stimulator)
  // Heart Failure (HFrEF) (VICTOR[2])
- **Asundexian** (FXIa Inhibitor)
  // 2º Stroke Prevention (OCEANIC-STROKE)
- **Aflibercept 8mg** (VEGF Inhibitor)
  // Retinal Vein Occlusion (QUASAR)
- **Gadoquatrane** (High Relaxivity Contrast Agent)
  // Magnetic Resonance Imaging (QUANTI-CNS, QUANTI-OBR)

Submissions

- **Darolutamide** (AR Inhibitor)
  // US, EU: Prostate Cancer (mHSPC) (ARANOTE)
- **Elinzanetant** (Neurokinin-1,3 Rec Antagonist)
  // US, EU: Vasomotor Symptoms
- **Aflibercept 8mg** (VEGF-Inhibitor)
  // CN: Neovasc. Age-rel. Macular Degen. (nAMD)

- **Acoramidis[4]** (TTR-Stabilizer)
  // EU: Transthyretin Amyloid Cardiomyopathy

Oncology
Cardiovascular+[3]
Neurology & Rare Diseases
Immunology
Others

New molecular entity
Life cycle management

Protein Therapeutics | Cell Therapy | Contrast Agent | Genetic Medicine | Radionuclide Therapy | Small Molecule

1 Bayer and partner sponsored + 3rd party label enabling studies with first patient first visit
2 Conducted by Merck & Co **3** Including Precision Cardiovascular, Nephrology & Acute Care
4 Exclusive commercialization rights acquired for EU markets; pending marketing authorization approval. Submission to EMA under responsibility of BridgeBio